FMR LLC & Abigail Johnson Trim ACADIA PHARMACEUTICALS Stake to 3.207%

Ticker: ACAD · Form: SC 13G/A · Filed: 2024-02-09T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, portfolio-change

TL;DR

**FMR LLC and Abigail Johnson just cut their ACADIA PHARMACEUTICALS stake to 3.207%.**

AI Summary

FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in ACADIA PHARMACEUTICALS INC. As of February 9, 2024, they collectively beneficially own 5,265,357 shares of common stock, representing 3.207% of the company. This is an amendment (Amendment No. 18) to a previous filing, indicating a slight reduction in their reported stake, which could signal a shift in their investment strategy for Acadia.

Why It Matters

A reduction in ownership by a large institutional investor like FMR LLC can sometimes be interpreted as a lack of conviction in the stock's short-term prospects, potentially influencing other investors' decisions.

Risk Assessment

Risk Level: low — This filing indicates a minor change in institutional ownership, which typically carries a low direct risk to the company's operations or immediate stock price.

Analyst Insight

Investors should note this minor reduction in institutional ownership by FMR LLC, but it's unlikely to be a primary driver for investment decisions. It's prudent to monitor future filings for more significant changes in ownership by major institutions and combine this information with other fundamental and technical analysis.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

Who are the primary reporting persons in this SC 13G/A filing?

The primary reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing for each reporting person.

What is the total number of ACADIA PHARMACEUTICALS INC common stock shares beneficially owned by FMR LLC and Abigail P. Johnson?

FMR LLC and Abigail P. Johnson each beneficially own 5,265,357 shares of ACADIA PHARMACEUTICALS INC common stock, as reported in Item 7 on their respective cover pages and Item 4(a) for FMR LLC.

What percentage of ACADIA PHARMACEUTICALS INC's common stock do the reporting persons own?

The reporting persons, FMR LLC and Abigail P. Johnson, each own 3.207% of ACADIA PHARMACEUTICALS INC's common stock, as indicated in Item 11 on their respective cover pages and Item 4(b) for FMR LLC.

What rule is this Schedule 13G/A filed under?

This Schedule 13G/A is filed pursuant to Rule 13d-1(b), as indicated by the checked box on the first page of the filing.

What is the CUSIP number for ACADIA PHARMACEUTICALS INC common stock?

The CUSIP number for ACADIA PHARMACEUTICALS INC common stock is 004225108, as stated in Item 2(e) of the filing.

From the Filing

EDGAR Filing Documents for 0000315066-24-000977 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home Company Search Current Page Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] SEC Accession No. 0000315066-24-000977 Filing Date 2024-02-09 Accepted 2024-02-09 08:35:54 Documents 1 Document Format Files Seq Description Document Type Size 1 filing.txt SC 13G/A 6630 Complete submission text file 0000315066-24-000977.txt 8314 Mailing Address 245 SUMMER STREET BOSTON MA 02210 Business Address 245 SUMMER STREET BOSTON MA 02210 6175706339 FMR LLC (Filed by) CIK : 0000315066 (see all company filings) EIN. : 043532603 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A SIC : 0000 Mailing Address 12830 EL CAMINO REAL SUITE 400 SAN DIEGO CA 92130 Business Address 12830 EL CAMINO REAL SUITE 400 SAN DIEGO CA 92130 858-558-2871 ACADIA PHARMACEUTICALS INC (Subject) CIK : 0001070494 (see all company filings) EIN. : 061376651 | State of Incorp.: DE | Fiscal Year End: 1231 Type: SC 13G/A | Act: 34 | File No.: 005-80011 | Film No.: 24611377 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)

View on Read The Filing